Iwamoto K, Watanabe J, Yamada M, Atsumi F, Matsushita T
J Pharm Pharmacol. 1987 Jun;39(6):421-5. doi: 10.1111/j.2042-7158.1987.tb03413.x.
Presystemic elimination of levodopa (20 mg kg-1) has been studied in 5- to 104-week-old male Wistar rats. The gastrointestinal and hepatic contribution to the overall first-pass effect was estimated separately after the drug had been administered intravenously, orally and intraportally. The contribution of the gut to the overall first-pass effect of this drug was greater than that of the liver in any age-group of the rats. Both the overall and intestinal first-pass effects of levodopa were greatest in 11-week-old rats and relatively small in both young (between weeks 5 and 7) and aged (between weeks 52 and 104) rats. In contrast, the hepatic first-pass effect did not show any significant age-dependent change. Age-related change in the jejunal blood flow could not explain the unique age-dependence in the intestinal first-pass metabolism of levodopa. However, the present age-dependence in the oral systemic availability of this drug between adult (11 weeks) and aged (52 to 104 weeks) rats was found to be similar to the tendency that has been reported between normal adult subjects and aged patients with Parkinson's disease.
已在5至104周龄的雄性Wistar大鼠中研究了左旋多巴(20毫克/千克)的首过消除。在静脉内、口服和门静脉内给药后,分别估计了胃肠道和肝脏对整体首过效应的贡献。在任何年龄组的大鼠中,肠道对该药物整体首过效应的贡献都大于肝脏。左旋多巴的整体和肠道首过效应在11周龄大鼠中最大,在幼龄(5至7周)和老龄(52至104周)大鼠中相对较小。相比之下,肝脏首过效应未显示出任何显著的年龄依赖性变化。空肠血流量的年龄相关变化无法解释左旋多巴肠道首过代谢中独特的年龄依赖性。然而,发现该药物在成年(11周)和老龄(52至104周)大鼠之间口服全身可用性的当前年龄依赖性与正常成年受试者和帕金森病老龄患者之间报道的趋势相似。